Equities analysts expect that Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) will report earnings per share of ($0.20) for the current fiscal quarter, Zacks reports. Zero analysts have made estimates for Brainstorm Cell Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.24) and the highest estimate coming in at ($0.15). Brainstorm Cell Therapeutics posted earnings of ($0.25) per share during the same quarter last year, which would indicate a positive year over year growth rate of 20%. The business is expected to announce its next quarterly earnings results on Wednesday, August 4th.
According to Zacks, analysts expect that Brainstorm Cell Therapeutics will report full year earnings of ($0.82) per share for the current fiscal year, with EPS estimates ranging from ($0.90) to ($0.73). For the next year, analysts forecast that the business will post earnings of ($0.40) per share, with EPS estimates ranging from ($0.79) to $0.00. Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that follow Brainstorm Cell Therapeutics.
Brainstorm Cell Therapeutics (NASDAQ:BCLI) last issued its quarterly earnings results on Sunday, April 25th. The biotechnology company reported ($0.19) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.26) by $0.07.
Institutional investors have recently modified their holdings of the stock. Citigroup Inc. lifted its holdings in Brainstorm Cell Therapeutics by 122.3% during the fourth quarter. Citigroup Inc. now owns 9,163 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 5,041 shares during the period. Advisory Services Network LLC bought a new stake in shares of Brainstorm Cell Therapeutics in the first quarter valued at $38,000. HighTower Advisors LLC bought a new stake in shares of Brainstorm Cell Therapeutics in the first quarter valued at $40,000. Cubist Systematic Strategies LLC bought a new stake in shares of Brainstorm Cell Therapeutics in the first quarter valued at $42,000. Finally, Raymond James Financial Services Advisors Inc. bought a new stake in shares of Brainstorm Cell Therapeutics in the fourth quarter valued at $54,000. Institutional investors and hedge funds own 23.10% of the company’s stock.
Brainstorm Cell Therapeutics Company Profile
Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.
Further Reading: Options Trading – What is a Straddle?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.